We are excited to announce that our lead drug candidate SUL-238 has been featured in the prestigious journal Nature Medicine. The article highlights hibernation as a source of inspiration for drug development, which also forms the basis for our groundbreaking medication, SUL-238.
SUL-238 is recognized as the only drug currently being tested in humans, developed from this hibernation-inspired approach. SUL-238 shows potential for treating Heart Failure, Alzheimer’s, Chronic Kidney Disease, aging, and other conditions. As a first-in-class drug with a unique mechanism of action, it protects mitochondrial function in both chronic and acute situations.
In collaboration with GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) clinical Phase I trial is currently ongoing to investigate the safety, tolerability and pharmacokinetics after single and repeated doses of SUL-238 in human as the first step towards patient benefit.
For more information please contact us, we are happy to answer your inquiry! If you are inclined towards investment in this pioneering pharmaceutical compound, we invite you to reach out to us.